Key Takeaways GSK's Specialty Medicines sales jumped 17% in Q1 2025, driven by HIV and oncology product strength. GSK expects low double-digit Specialty Medicines growth in 2025 despite IRA related headwinds. New approvals like Nucala for COPD and strong launches like Blujepa support the growth trajectory.GSK plc’s (GSK) Specialty Medicines segment includes medicines that prevent and treat diseases like HIV, cancer, asthma and immune-inflammation diseases like lupus. Specialty Medicines now represents clo ...

Key Takeaways GSK's Specialty Medicines unit drove 19% growth in 2024 and 17% in Q1 2025, led by HIV and oncology drugs. New U.S. approvals and strong research momentum support GSK's pipeline across respiratory, HIV and oncology. GSK trades at a forward P/E of 8.63, below the industry average, and continues to outperform peers and market.GSK (GSK) stock has risen 21.5% in the past six months. The consistently strong performance of the Specialty Medicines unit, regulatory and pipeline successes and an opti ...

Core Viewpoint - The experimental drug Itepekimab, developed by Sanofi and Regeneron for treating chronic obstructive pulmonary disease (COPD) in former smokers, has shown mixed results in late-stage trials, leading to significant stock price declines for both companies [1][2]. Group 1: Company Performance - Sanofi's stock price fell by 6.17% and Regeneron's stock price dropped by 13.77% following the announcement of the trial results [1]. - The late-stage trials for Itepekimab produced contrasting outcomes, with one trial showing a 27% reduction in disease worsening, while the other did not demonstrate the same efficacy despite initial positive results [1]. Group 2: Drug Development Insights - Analysts are closely monitoring the trial data for Itepekimab, especially as Sanofi's key drug Dupixent is nearing patent expiration, which has been a significant growth driver for the company [2]. - The mixed results of Itepekimab represent a major setback for Sanofi and Regeneron, potentially delaying the drug development process by at least three years [2]. - Other pharmaceutical companies, such as GlaxoSmithKline, are also developing treatments for COPD, with GlaxoSmithKline's Nucala recently approved for use in the U.S. [2].

Market Overview - Wall Street has experienced volatility in 2025 due to overstretched valuations of U.S. stocks, persistent inflation, weak economic data, geopolitical conflicts, and concerns regarding the Trump administration's trade policies [1] - The Federal Reserve's uncertainty over rate cuts, recession fears, and the emergence of a low-cost Chinese AI platform have contributed to investor unease [1] Investment Strategy - It is advisable to invest in high dividend-paying corporate giants, which typically possess strong financial positions, robust business models, and globally recognized brand value [2] - Regular dividend payments from these firms can provide a steady income stream during market fluctuations [2] Company Highlights Philip Morris International Inc. (PM) - Zacks Rank 1, benefiting from strong pricing power and an expanding smoke-free product portfolio, aiming to become substantially smoke-free by 2030 [6][7] - Expected revenue and earnings growth rates of 8.1% and 13.7% respectively for the current year, with a current dividend yield of 3.01% [8] CVS Health Corp. (CVS) - Zacks Rank 2, investing in technology to reduce costs and enhance customer experience, with plans to close 271 stores to save over $500 million in 2025 [9][10] - Expected revenue and earnings growth rates of 3.7% and 12.6% respectively for the current year, with a current dividend yield of 4.34% [10] Energy Transfer LP (ET) - Zacks Rank 2, benefiting from long-term fee-based contracts, with nearly 90% of earnings from such contracts [11][13] - Expected revenue and earnings growth rates of 18.2% and 12.5% respectively for the current year, with a current dividend yield of 7.30% [13] GSK plc (GSK) - Zacks Rank 2, strong position in HIV and Vaccines, with increased sales growth in Specialty Medicines and promising new products [14][15] - Expected revenue and earnings growth rates of 5.1% and 6.7% respectively for the current year, with a current dividend yield of 4.28% [16] NatWest Group plc (NWG) - Zacks Rank 1, providing a range of banking and financial services in the UK and internationally [17][18] - Expected revenue and earnings growth rates of 20.1% and 17.3% respectively for the current year, with a current dividend yield of 5.41% [19]

报告摘要 市场表现： 2025 年5 月23 日，医药板块涨跌幅+0.42%，跑赢沪深300 指数1.23pct，涨跌幅居申万31 个子行业第2 名。各医药子行业中，医疗设备(+1.43%)、医疗研发外包(+0.98%)、线下药店（+0.74%）表现居前，疫 苗（-0.68%)、血液制品(-0.43%)、医院（-0.27%)表现居后。个股方面，日涨幅榜前3 位分别为新天地 (+20.02%)、海辰药业(+20.00%)、多瑞医药(+20.00%)；跌幅榜前3 位为亚虹医药（-5.86%）、百济神州 (-4.15%)、润都股份（-3.94%)。 行业要闻： 近日，GSK 宣布，美国FDA 批准其"first-in-class"抗体疗法Nucala（Mepolizumab）作为辅助维持治疗， 用于伴有嗜酸性粒细胞表型、病情控制不佳的成人慢性阻塞性肺病（COPD）患者。Nucala 是一种靶向 IL-5的单克隆抗体，已开发用于治疗一系列与2 型炎症相关的IL-5 介导疾病。 该药是首个在临床表现多样COPD 人群中开展研究并获批用于嗜酸性粒细胞表型患者的生物制品，该疾 病表型以血液嗜酸性粒细胞计数（BEC）≥150 ...

Core Viewpoint - GSK's Nucala has received FDA approval for a fifth indication, allowing it to treat certain patients with chronic obstructive pulmonary disease (COPD), marking a significant expansion of its therapeutic applications [1][3]. Group 1: Product Approval and Indications - Nucala is now approved as an add-on maintenance treatment for adult patients with inadequately controlled COPD and an eosinophilic phenotype [1]. - The drug is already approved for severe asthma, chronic rhinosinusitis with nasal polyps, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome in various regions, including the U.S. and Europe [2]. - The approval was supported by data from the late-stage MATINEE study, which demonstrated a significant reduction in the annualized rate of moderate to severe exacerbations when Nucala was added to inhaled maintenance therapy [3]. Group 2: Market Context and Competition - The FDA's decision makes Nucala the second biologic treatment approved for COPD and the third new COPD drug approved in the U.S. in the past year [9]. - Nucala will compete directly with Sanofi and Regeneron's Dupixent, which was the first biologic treatment for COPD approved in September of the previous year [10]. - Verona Pharma's Ohtuvayre was also approved last year as the first inhaled product with a novel mechanism of action for COPD maintenance treatment in over 20 years, highlighting the competitive landscape [11]. Group 3: Company Strategy and Financial Outlook - GSK aims to generate over £40 billion in annual sales by 2031, focusing on therapeutic areas such as HIV, immunology/respiratory, and oncology [5]. - The company expects to launch five new products or line extensions this year, with three already approved in the first half of 2025 [6]. - Year-to-date, GSK shares have gained 15%, outperforming the industry, which has seen a 6% decline [7].

Nucala和Dupixent等生物药物为COPD患者提供了更多治疗选择，到目前为止，这些患者的治疗主要依 吸入器、类固醇和专门的运动项目等治疗方法。 Murphy表示，市场营销"将尝试将其中一种药物与另一种药物进行对比"，但考虑到替代方案有限，两 种药物都将获得"显著的市场认可" 。Nucala每四周注射一次，而Dupixent每两周注射一次。 葛兰素史克首席商务官Luke Miels在4月份的财报电话会议上表示，公司认为Nucala与Dupixent竞争非常 激烈。他表示，葛兰素史克一直在密切关注Dupixent的上市情况，包括赛诺菲的市场准入、患者基础以 及人们使用该药物的原因。 Miels在另一场会议上表示，该公司对Nucala的初始销售持谨慎态度。该药物将主要由肺科医生开具用 于治疗COPD，这些医生会向一小部分患者推荐生物药物。他表示："将会有一段时间的实验、应用和 培训。" 智通财经APP获悉，葛兰素史克(GSK.US)治疗一种致命肺部疾病的药物获得美国批准，加剧了与竞争 对手赛诺菲(SNY.US)的竞争。据悉，美国食品和药物管理局(FDA)批准葛兰素史克的Nucala作为部分慢 性阻塞性肺病( ...

GSK plc (GSK) announced that it has signed an agreement with Massachusetts-based biopharmaceutical company Boston Pharmaceuticals to acquire the latter’s lead pipeline drug, efimosfermin alfa.Efimosfermin is an investigational long-acting variant of FGF21 protein designed to treat and prevent the progression of steatotic liver disease (SLD), commonly known as fatty liver disease. Boston Pharma is currently evaluating the drug in mid-stage studies for metabolic dysfunction-associated steatohepatitis (MASH), ...

We expect GSK plc (GSK) to surpass expectations when it reports first-quarter 2025 earnings on April 30, before the opening bell. The company’s earnings beat estimates by 11.32% in the last reported quarter.The Zacks Consensus Estimate for sales and earnings is pegged at $9.54 billion and $1.08 per American depositary share (ADS), respectively. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)Factors Shaping GSK’s Upcoming ResultsGSK reports financial figures under three segments — S ...